A 2.5-Year Within-Patient Evolution of Pseudomonas aeruginosa Isolates with In Vivo Acquisition of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistance upon Treatment

Abstract excerpt

Ceftolozane-tazobactam is considered to be a last-resort treatment for infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa . Although resistance to this antimicrobial has been described in vitro , the development of resistance in vivo has rarely been reported. Here, we describe the evolution of resistance to ceftolozane-tazobactam of P. aeruginosa isolates recovered from the same patient during...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibiotic Resistance in Bacteria
• Share to Antibiotics Pharmacokinetics and Efficacy
• Share to Pneumonia and Respiratory Infections